Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Metastatic HER2-negative Breast Cancer with APOBEC3B Deletion
NCT03989089Phase 2Active, not recruiting
- Sponsor
- Universiti Malaya
- Start
- Jul 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by Universiti Malaya. Started Jul 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03989089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989089.